American Chemical Society
jm2c00190_si_001.pdf (496.13 kB)

Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer

Download (496.13 kB)
journal contribution
posted on 2022-06-27, 14:07 authored by Dipti Kanabar, Mimansa Goyal, Emma I. Kane, Tejashri Chavan, Abbas Kabir, Xuechun Wang, Snehal Shukla, Joseph Almasri, Sona Goswami, Gizem Osman, Marino Kokolis, Donald E. Spratt, Vivek Gupta, Aaron Muth
Gankyrin is an oncoprotein responsible for the development of numerous cancer types. It regulates the expression levels of multiple tumor suppressor proteins (TSPs) in liver cancer; however, gankyrin’s regulation of these TSPs in breast and lung cancers has not been thoroughly investigated. Additionally, no small-molecule gankyrin inhibitor has been developed which demonstrates potent anti-proliferative activity against gankyrin overexpressing breast and lung cancers. Herein, we are reporting the structure-based design of gankyrin-binding small molecules which potently inhibited the proliferation of gankyrin overexpressing A549 and MDA-MB-231 cancer cells, reduced colony formation, and inhibited the growth of 3D spheroids in an in vitro tumor simulation model. Investigations demonstrated that gankyrin inhibition occurs through either stabilization or destabilization of its 3D structure. These studies shed light on the mechanism of small-molecule inhibition of gankyrin and demonstrate that gankyrin is a viable therapeutic target for the treatment of breast and lung cancer.